搜尋
Transcode Therapeutics Inc
RNAZ添加自選
6.600USD
-0.280-3.95%
收盤 05/15, 16:00（美東）報價延遲15分鐘
6.05M總市值
虧損本益比TTM
關於 Transcode Therapeutics Inc 公司
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc簡介
公司代碼RNAZ
公司名稱Transcode Therapeutics Inc
上市日期Apr 28, 2021
CEOCalais (Philippe P)
員工數量7
證券類型Ordinary Share
年結日Apr 28
公司地址6 Liberty Square
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02109
電話18573016857
網址https://www.transcodetherapeutics.com/
公司代碼RNAZ
上市日期Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 5月14日 週四
更新時間: 5月14日 週四
持股股東
股東類型
持股股東
持股股東
佔比
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
Geode Capital Management, L.L.C.
1.20%
UBS Financial Services, Inc.
0.90%
Vanguard Capital Management, LLC
0.71%
其他
83.57%
持股股東
持股股東
佔比
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
Geode Capital Management, L.L.C.
1.20%
UBS Financial Services, Inc.
0.90%
Vanguard Capital Management, LLC
0.71%
其他
83.57%
股東類型
持股股東
佔比
Corporation
9.08%
Investment Advisor/Hedge Fund
5.73%
Investment Advisor
2.66%
Individual Investor
0.14%
Hedge Fund
0.10%
其他
82.29%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
37
77.85K
8.49%
-42.31K
2025Q4
36
70.82K
7.72%
-29.38K
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
CK Life Sciences International Holdings, Inc.
83.28K
9.08%
+83.28K
--
Oct 27, 2025
Sabby Management, LLC
41.60K
4.54%
+41.60K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
5.27K
0.58%
--
--
Jan 31, 2026
UBS Financial Services, Inc.
2.96K
0.32%
+2.96K
--
Dec 31, 2025
The Vanguard Group, Inc.
6.54K
0.71%
--
--
Feb 28, 2026
Tracy (Thomas Joseph)
1.25K
0.14%
+1.25K
--
Mar 07, 2025
Tower Research Capital LLC
887.00
0.1%
+745.00
+524.65%
Dec 31, 2025
SBI Securities Co., Ltd.
10.00
0%
--
--
Dec 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
公告日期
除權除息日
類型
比率
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
查看更多
